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Summary 
Objective: To review the recreational use of ketamine (‘Special K’; KET) and explore 
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the recent diffusion of its new derivative methoxetamine (‘Special M’; MXE). 
Methods: The literature search on the non-clinical/recreational use of KET and MXE 
was carried out in a range of medical databases. Considering the limitations of peer-
reviewed information, data were integrated with a qualitative assessment of a range of 
websites, drug fora and other online resources including. Results: The recreational use 
of KET has started since its discovery in 1962. This was due to its rapid onset, short 
duration of action, and peculiar psychotropic effects (‘K-hole’). The latter effect ranges 
from confusion to dissociation and depersonalization (near-death experience). However, 
KET abuse is often associated with physical and psychological side effects of which the 
worst is urological/bladder toxicity. Recently, MXE has emerged as a legal and ‘bladder 
friendly’ KET alternative. MXE presents with the same dissociative effect of KET but 
with slower onset and longer duration of action. However, MXE seems to be associated 
with worse side effects than KET, ranging from mood disturbances/suicidal attempts to 
acute cerebellar toxicity. Conclusions: After 50 years of its discovery, KET has led to 
the emergence of MXE. However, this latter derivative does not appear to be a safer 
alternative to KET itself.  
 
 
Keywords: Ketamine, methoxetamine, near-death experience, phencyclidine, 
psychoactive. 
Introduction  
Ketamine (KET) is a phencyclidine (PCP) derivative that blocks non-competitively the 
glutamate N-Methyl-D-Aspartate (NMDA) receptor; consequently, it inhibits the 
excitability of pain neurons to induce its dissociative anaesthetic activity [1-3]. It binds 
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as well but with a lower affinity to σ and µ opioid receptors [1]. KET also inhibits nitric 
oxide synthase, hence further contributing to analgesia [1].  Furthermore, it acts as a 
noradrenergic and serotonergic uptake inhibitor, both neurotransmitters being involved 
in descending anti-nociceptive pathways [4, 5]. Since KET binds to both σ(1) and σ(2) 
receptors with μM affinities, this may suggest that σ receptor-mediated neuronal re-
modelling may contribute to the antidepressant effects of KET [6]. Regarding MXE, its 
pharmacology and toxicology have yet to be elucidated. Although no formal studies 
have demonstrated the mechanism of action of MXE, it is likely to share the mechanism 
of action of KET through NMDA receptor antagonism and inhibition of dopamine 
reuptake [7]. 
KET dissociative activity involves the sensory loss and analgesia as well as amnesia 
which are not accompanied by actual loss of consciousness [8]. This unique experience 
could expand to the sense of a near-death experience (NDE) or even body splitting. For 
instance, Barbara Collier, an anaesthetist commented: ‘Ketamine allows some patients 
to reason that . . . the strange, unexpected intensity and unfamiliar dimension of their 
experience means they must have died’ [9]. 
KET causes mild stimulation of the cardiovascular (CVD) system without suppression 
of the respiration and gag reflex; thus, it has a good safety record [10]. It is used in the 
UK in both Emergency Departments (EDs) and chronic pain clinics for mild anesthesia 
in surgeries [11]. Furthermore, KET has been used as a therapeutic tool in a range of 
remaining conditions, including: assisted psychotherapy for people with heroin 
dependence [12]; alcoholism [13, 14]; resistant depression [15]. Furthermore, it has 
been reported that low dose KET can also re-create a number of physiologic 
abnormalities characteristic of schizophrenia [16,17]. However, administration of the 
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drug in high doses for recreational purposes can cause CVD and respiratory toxicity. 
This makes its unregulated use outside the controlled environments a concern [18]. KET 
is an arylcyclohexylamine derivative with a molecular weight of 237.73 g/ mol. Its 
molecular formula is 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone (Figure 1). 
KET has three modifications from the PCP main structure [19] (Figure 1). The first 
modification involves the replacement of the piperidine ring by a methylamine which 
gives the same potency as PCP but increased tendency to induce nausea. The second 
modification involves the two chloro to the phenyl ring, which decreases the potency 
but increases the analgesic effect activity. The third substitution involves the addition of 
carbonyl group to the cyclohexyl ring which increases the elimination and decreases the 
duration of action of the anaesthetic activity. KET has one chiral centre at the C-2 
carbon and thus has two enantiomers (R and S enantiomers). The S enantiomer has the 
more potent analgesic properties; whereas, the postsynaptic properties and agitated 
behavior is more associated with R enantiomer [2, 20].  
Regarding pharmacokinetics, KET is extensively metabolized by N-demethylation 
producing norketamine, a non-competitive NMDA receptor antagonist which might also 
exhibit enantioselective pharmacological activity, e.g. (S)-norketamine has an 8-fold 
higher affinity than (R)-norketamine [21]. The pharmacokinetics of KET in analgesic 
doses after intravenous (IV), intramuscular (IM), and oral administration was 
investigated in healthy volunteers [22]. Plasma KET concentration-time curves were 
fitted by a two-compartment open model with a terminal half-life of 186 min. 
Absorption after IM injection was rapid and the bio-availability was 93%. However, 
only 17% of an oral dose was absorbed because of extensive first-pass metabolism. This 
high rate of first pass metabolism may well explain why KET is typically not ingested. 
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Similarly, MXE is generally taken by nasal insufflation (snorting), sublingual 
application, and IV and IM injection, with rectal use having been reported as well [7].  
The objective of this paper is to comment on both the recreational use of KET along 
with its side effects and toxicity and one its new derivatives, known as methoxetamine 
(MXE). The latter seems to be particularly popular compared to others such as N-
Ethylnorketamine; methoxyketamine; 3-MeO-PCP; or remaining derivatives, including 
tenocyclidine (TCP) and tiletamine (for a review of the grey literature) [23,24].  
 
Methods  
The literature search on the non-clinical/ recreational use of KET and MXE was carried 
out in six databases including: Ingenta, PubMed, Sciencedirect, Scopus, Web of 
Knowledge and Wiley. Considering the limitations of peer-reviewed data in relation to 
latest trends of abuse and new psychoactive substances [11], such as MXE, results were 
integrated with a qualitative assessment of a range of websites, drug fora and other 
online resources including: E-newsgroups, chatrooms, mailing lists, e-newsletters, and 
bulletin boards. The keywords used in this study included: KET, ketamine, ‘Special K’, 
2-(2-chlorophenyl)2-2(methylamino)cyclohexanone, phencyclidine, PCP, MXE, 
‘Special M’, 2-(3-methoxyphenyl)-2-amino)cyclohexanone, methoxetamine, MXE-
Powder, METH-O, ‘Special M’, psychedelics, near-death experience, NDE, 
recreational. The search was performed over a period of 10 months (January 2011 - 
October 2011) in eight languages including: English, Flemish, German, Hungarian, 
Polish, Italian and Spanish. The inclusion criteria were any studies showing the 
chemistry, pharmacology, psychedelic and recreational use of KET and/or MXE. Non 
relevant studies were excluded. To this respect, the initial search retrieved 246 studies 
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of which 95 were excluded. The authors ended up with 151 studies being monitored on 
a regular basis and included 108 websites, 41 peer-reviewed data, one newsletter and 
one monograph (see diagram 1). Data collected were kept confidential in a password-
protected online database of the ReDNet (www.rednetproject.eu). Any personal data 
(that could be identifiable) collected from online fora was kept anonymous. The study 
was cleared for ethical approval by the School of Pharmacy Ethics Committee, Hatfield, 
Hertfordshire, UK (15 December 2010, PHAEC/ 10 – 42).  
 
Results 
Non-clinical use of KET 
KET non-clinical use has increased exponentially since its first discovery as a safer 
anaesthetic alternative to PCP [1, 20]. It was discovered in 1962 by Calvin Stevens, a 
consultant for Parke-Davis/ Warner [1, 20].  In 1965 its first use as a recreational drug 
was recorded [20]. However, the recreational use became well-known from the mid-
1990s, when it was more popular than cocaine. This was partly because cocaine purity 
dropped and it was sold as a cheaper alternative [25]. KET, also known in these 
contexts as ‘Special K’ or simply ‘K’, is widely used as a recreational drug in clubs, 
raves and squat parties for self-experimental purposes and it has caused problems as 
such in the EU and internationally. It might be difficult to understand why an 
anaesthetic could become a popular substance of misuse.  A few reasons can be 
identified [7, 26]. These include its (a) short time-to-effect 30 seconds IV, 5 - 30 
minutes intranasally and 20 minutes orally) and duration of action which can last up to 
three hours, (b) low cost, (c) peculiar psychotropic effects. The latter, known among 
users as the ‘K-hole’ [27] range from confusional states, vivid dreams, hallucinations, 
flashbacks, referential thinking, dissociation and depersonalization to psychotic 
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experiences. It is known that at sub-anaesthetic doses, KET intake has been anecdotally 
described to be associated with effects somewhat similar to those reported during a 
near-death experience (NDE) [8, 28-30]. NDEs usually occur in various situations 
including: cardiac arrest [31]; hypovolaemic/ septic/ anaphylactic shock; intra-cerebral 
haemorrhage; cerebral infarction; near-drowning or asphyxia; apnoea; electro-
stimulation of the temporal lobe [32] and prolonged isolation/sensory deprivation [33]. 
Common features of the NDE experience include: (a) the ineffable nature of the 
experience; (b) a sense of joy (cocaine like rush), peace and love; (c) the detachment 
from own physical body (out-of-body experiences) [34]; (d) traveling along a region of 
darkness towards a light at the end; (e) visualization of past experiences, sometimes 
organized into a life-review [28, 35]; (f) visions and communications with deceased 
relatives and friends or ‘beings of light’; (g) a decision to return to life and (h) altered 
perception of time, ataxia, among others [35].  
Users reporting the near-death experiences felt out of the body or lost their senses and 
sometimes were feeling as out of the planet. One user, Mr. P, reported the above effects 
after he injected 100 mg of KET IM while he was listening to a piece of music. He said: 
“I gradually lost my senses. The music was very distorted. I tested myself by asking 
basic questions about mathematics, the names of those I love, etc., then suddenly I 
wasn’t interested in this anymore. So I tried to concentrate on ‘who I am’ and I lost the 
interest again. Visions become blurred. It wasn’t meaningful who I was any more, 
because I existed anyway. Then I tried the experience of death. I was going down a 
tunnel. I saw the planet Earth. I could feel the relationship between the human soul, 
Earth and the planets. I thought I was a doll, you know the matryoshka? I was the 
matryoshka of the entire system. I understood that earth is inside something else. I felt 
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its gravity. All this is embraced within a system. I was nothing, but I knew that my 
place was on Earth” [30]. 
Another KET user reported: “Two years ago I was with my friends in Valencia. We 
went to the beach that day and we had some KET. We sat on the sand. The effects 
started very soon. I felt dizzy and I had to lie down. I closed my eyes. The first thing 
that I remember is that I felt somehow I was going very fast and that I left my body. It 
was not frightening. Subsequently, I saw a tunnel and a tiny little light which grew 
bigger and bigger. I was approaching this light when I heard a voice telling me to go 
back. So I asked ‘Why? I don’t want to go back.’ I had no reply. A being of light 
appeared. He wanted to show me something. A big screen also appeared. I saw earth 
and the planets. I have heard them breathing. I touched the stars and talked to the Sun 
(God). I cannot remember what he said but it was amazing. I kept thinking that it was 
wonderful and amazing. And then, suddenly, I was lying back on the beach!” 
KET effects and NDEs might bear some level of resemblance at a neurobiological level 
as well. In fact, both KET and NDEs involve events at glutamate N-methyl-D-aspartate 
(NMDA) receptors [8,29,36]. However, it is still unclear if reported KET psychoactive 
effects may appropriately fit into typically described features of an NDE.  
 
Adverse reactions associated with ketamine misuse 
Miss L., a 23-year-old who tried KET only once in her life at a disco club, observed: “I 
felt a bit paranoid, I was going to die. The first effects started very soon. I felt very 
confused and normal reality just disappeared. I was dizzy and unable to walk. I started 
bumping against walls. I wanted to go out from the room where I was, but it was very 
cold. I had no-one close to help me.” [30]. 
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The risk of physical harm from accidents, such as blackouts and bad falls, is also very 
high [18]. There are also reports of people with chronic opiate problems using KET for 
its anaesthetic and analgesic effects [37, 38].  
KET may lead to dependence and tolerance can develop quickly; hence a larger quantity 
is required in order to achieve the same effects [18]. This can lead users to take it in 
intense ‘binges’. An immediate risk of taking KET in recreational settings is accidents, 
such as bad falls. The disconnection from the body can be dangerous in almost any 
situation other than lying down in a safe environment. Other adverse effects can include 
panic attacks and depression, and when taken in large doses it can exaggerate pre-
existing mental health problems [19,30,39]. Stimulant-like weight loss and loss of 
appetite have also been reported after periods of heavy use. The risks of KET use are 
increased if it is used with depressant drugs, such as alcohol. It can suppress breathing 
and heart function in rare cases, although more commonly it stimulates these functions. 
It is more likely to suppress breathing (i.e. give rise to a period of apnea) if taken as a 
fast IV [18]. When used with stimulant drugs such as ecstasy (MDMA) or 
amphetamines, it can also cause high blood pressure [3]. A number of reports suggest 
that KET can be used as a ‘date rape drug’ as high doses can cause amnesia for events 
that happened while under the influence of the drug [27]. Three days after consumption 
of KET, impairments of working, episodic and semantic memory have been reported 
[40,41]. One research study has shown that semantic memory impairments associated 
with recreational KET use are reversible after people stop or substantially reduce its 
use. However, impairment to episodic and possibly attentional functioning is longer 
lasting [41-43]. A problem with these studies is that the authors rarely, if ever, provide 
urine or hair test results to prove that their subjects are not misusing with other drugs at 
10 
10 
the time of testing. Cannabis and alcohol are particularly likely culprits as many KET 
users smoke cannabis and drink alcohol daily [27]. Some users also experience mild 
forms of schizophrenic-like symptoms and perceptual distortions associated with the 
use of KET for a short period after they have stopped taking the drug [26]. Initially, 
following its anaesthetic use, clinicians reported the occurrence of confusional states, 
vivid dreams and hallucinations as well as flashbacks [44]. The risk of death in has been 
commented in a few reports [18]. According to a report by the European Monitoring 
Centre for Drugs and Drug Addiction [37], some 12 persons have died as a result of 
KET use (seven in the US, and five in Europe) in the previous 10 years. Only three of 
these deaths were associated with the ingestion of KET on its own [37]. Conversely, 
Schifano et al [18] focused in KET misuse mortality figures (UK; 1993 – 2006), 
extracted from various sources and identified 23 victims (typically males, in the age 25 
– 44 age group) who self-administered themselves with a miscellany of psychoactive 
compounds (including KET) and alcohol. KET was detected in four cases on its own 
and they suggested that KET high safe profile should be questioned. 
 
The bladder toxicity issues associated with KET cannot be disregarded. KET is linked 
to severe bladder problems including: incontinence, painful bladder, bladder shrinkage 
and damage to kidney and ureter obstruction which may lead to bladder removal [45-
47]. However, the mechanisms of how KET cause bladder toxicity are still somewhat 
unclear. 
 
MXE 
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The recent emergence of new synthetic drugs [7, 48], has also involved the ‘KET/ PCP-
like drugs’ market. Since 2010, MXE has been advertised and sold online as a legal 
alternative to KET [7, 49]. Indeed, MXE can be acquired legally without a veterinary 
licence which is the minimum requirement for the purchase of KET in various 
countries, including the US. In the UK, it became the first drug to be banned by the 
Government under a temporary class drug order in April 2012. MXE chemical formula 
is 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (Figure 1). Its molecular 
weight is 283.79 g/ mol. It is available as a white or off-white hygroscopic powder. It 
differs from PCP by two modifications [7, 50]. The first involves the removal of the 
piperidine ring and replacement by an ethyl amino group which gives more potency 
than PCP but increases the tendency to induce nausea. The second modification 
involves the 3-methoxy substitution on the phenyl ring which increases the µ-opioid 
receptor affinity, whilst at the same time removing its mood altering effects. 
MXE is available online as ‘MXE powder’ and ‘Special M’ in the form of white 
powder. It is labelled as ‘Not For Human consumption’ in order to circumvent the 
regulations regarding recreational drugs [7].  MXE primary route of administration is 
intranasal, oral, sublingual, rectal and IM [51, 52]. In addition, very rare cases of IV 
administration have been reported and included an unconfirmed fatality following an IV 
injection of both 80 - 100 mg MXE and 400 mg of 5,6-methylenedioxy-2-aminoindane 
(MDAI) [51, 52]. 
MXE desired effects and dosages are influenced mainly by the modalities of intake. The 
dosages can range from 20 - 100 mg for oral administration and 10 - 50 mg for IM 
administration. Some users suggest the increase in the dosage gradually without 
exceeding 50 mg on the first occasion when administered orally [53].  The perceived 
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effect could be delayed of some 30 - 90 minutes after insufflation [54]. This might be 
dangerous as it often causes the user to ingest another dose of the substance [51], 
thinking that the first dose was inadequate. MXE duration of action has been described 
as being in the range of 5 - 7 hours [53]. However, when taken IM, the effect of MXE is 
faster than orally (within five minutes) [51] and its duration of action is shorter (about 
one hour). 
 
MXE desired effects and adverse reactions  
As reported by users, MXE effects are similar to KET but with longer delay in onset (90 
min) and longer duration (5 - 7 hours) when administered orally [51, 53]. MXE 
ingestion may be associated with NDE whose common features are: sensory 
deprivation, derealization and dissociation from the physical body [19, 47, 55].  
Its reported desired effects include:  euphoria, empathy, ‘cosiness’, pleasant 
intensification of sensory experiences especially whilst listening to the music, mild to 
strong sense of dissociation from the physical body, distortion of the sense of reality, 
vivid hallucinations, introspection, and brief anti-depressant effects [51, 53, 56, 57]. 
Users reports described MXE experience as:“music sounds great”, “trapped inside a 
glass chopping board”, “not for social situation”, “feeling like another inanimate 
object”,  “...just seems so absurdly surreal and it makes no sense, but I'm quite happy 
just to stare at the TV screen, feeling all snugly and warm”. Somebody described MXE 
as a “big Christmas cardigan”, whose intake was providing both “spinning sensations” 
and “naturalistic hallucinations in waves”, overall referring to the ‘M-hole’, as opposed 
to the KET ‘K-hole’ [51]. This described the subjective state of dissociation from the 
body, which may mimic the out-of-the-body experiences or NDE [18, 19]. Most users’ 
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reports concluded that MXE is different from KET mainly because of “longer come up” 
which might lead to a high risk of re-dose, and its longer lasting effects. In summary, 
MXE seems to work as a short-acting mood enhancer with powerful (visual) 
hallucinogenic and dissociative properties. However, it ingestion might be associated 
with several side effects as dizziness, confusion, time distortion, aphasia, synaesthesia, 
and psychomotor agitation [53, 57]. 
MXE withdrawal symptoms may include low mood and/ or depressive thoughts [53], 
decreased levels of cognitive impairment, insomnia [53], and potential suicidal attempts 
[51].   
MXE is allegedly used in combination with a variety of other drugs in order to enhance 
or prolong its effects and duration of action. These include LSD, 2CC (4-chloro-2,5-
dimethoxyphenethylamine), alpha-MT (alpha-methyltryptamine), MDAI [53]. 
However, web fora users do not recommend its consumption with alcohol, 
tetrahydrocannabinol (THC), selective serotonin reuptake inhibitors (SSRIs) or 
monoamine oxidase inhibitors (MAOIs). 
Some KET side effects such as agitation and CVD issues (e.g. increased heart rate and 
blood pressure) may be associated with MXE ingestion. Others have included painful 
bladder, ureter obstruction, papillary necrosis and hepatic dysfunction [27,47,58].  
Regarding MXE psychopathological disturbances, it may seem appropriate to conclude 
that they are similar to KET [59].  
Although MXE has been named as the ‘bladder friendly’ alternative to ‘Special K’, 
work is still needed to confirm that MXE is bladder friendly [47, 50]. Users, admitted to 
accident and emergency department after having ingested MXE, have experienced both 
KET-like dissociative/ catatonic and sympathomimetic effects such as agitation, 
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tachycardia, hypertension, hallucinations, confusion, stupor, mydriasis and nystagmus 
[47, 50]. MXE was detected in all the patients’ serum. Other patients had acute 
cerebellar toxicity after nasal insufflations of MXE [61]. The toxicity needed several 
days to recover and was characterised by: severe ataxia, slurred speech, nystagmus, 
incoordination and reduced consciousness. 
User reports on forums confirm these effects. For instance a chronic user, after 18 
months of taking MXE, reported that the drug’s effects were dose-dependent in most 
cases [62]. He specified his favourite route as sublingual compared to oral as the latter 
gives slower effect. In low doses (20 - 35 mg), MXE seemed more of a social drug as 
“It gave no hangover, lowered inhibitions enough that I could dance and not care if it 
was bad, and allowed me to feel inebriated enough that I didn’t feel like I was missing 
out on drinking”. However, at higher doses (> 40 mg), the dissociative effects started 
appearing as the user reported: “I found MXE very confusing, numbed the body and yet 
was still quite suitable for a rave or part setting where socialization would not be 
required...I occasionally investigated high doses on my own, but did not find them 
particularly to my liking. I prefer to be functional as I never have much spare time, so 
the “M-hole” was not great for me. I only investigated it once. Any time I took doses 
above 60 mg I found that I would awaken the next morning feeling “fuzz”...It is not 
necessarily an unpleasant feeling, but I certainly feel impaired and would not be 
comfortable driving a car while experiencing it. It is very hard sensation to describe, but 
I feel mentally dulled and my vision feels odd”. 
Another user have experienced the dissociative effect after about one hour of taking 80 
mg MXE sublingually with 15 mg of 1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane 
(2C-E) intranasally [57]. The user reported:”I became unable to follow the movie I was 
15 
 
watching while waiting for the chemicals to take effect...From this point on memory is 
spotty as my mind had deconstructed the concepts of time, order, and reality. Eyes are 
closed for the duration of the trip. Visuals were truly breathtaking, impossible to relate 
to my beloved trip report readers. I had the sensation that my body had descended 
several feet below the earth. I felt as though my mind had disconnected from the 
confines of its physical structure, projected astrally and was moving though time space 
at an incalculable speed...I believe I experienced ego death which was terrifying at first 
but afterward I felt ecstatic”.  
 
Discussion and Conclusions 
After 50 years of its discovery, KET or “Special K” has led to the emergence of 
methoxetamine , or “Special M”, and possibly other derivatives such as 3-MeO-PCP, 
PCE, 3-MeO-PCE, tiletamine and 1-(1-(2-thienyl)-cyclohexyl)morpholine (TCM). 
Most of these new substances share a number of characteristics that may constitute a 
public health challenge: (a) they are not approved for human consumption; (b) their 
intake is possibly associated with a number of unknown side effects/ adverse reactions); 
(c) very few related pharmacological/toxicological data are available in the peer-
reviewed, scientific, literature, with the limited knowledge being mostly restricted to 
pre-clinical studies; (d) they are rapidly appearing in always more sophisticated forms 
and remain unregulated for a long period of time; (e) they are most often synthesized in 
underground laboratories simply modifying the molecular structure of remaining 
controlled drugs, hence raising further concerns in terms of the presence of 
contaminating agents; (f) they are largely available online and thus ‘just a click’ away 
from our homes and potentially available to everyone [7]. In addition, the current legal 
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status of most of its derivatives may arguably facilitate the increasing levels of 
popularity of the drug, and might affect as well the users’ perception of risks associated 
with its consumption. In fact, the idea that legality can equate with safety still remains 
well grounded amongst some recreational users [18, 19]. This work has presented an 
overview of the first 50 years of KET’s history and provided an original refection on its 
role in the future. A possible limitation of the present study could be given by the fact 
that only publicly available websites, fora and similar sources were monitored. 
Conversely, to improve the coverage of the study not only the web pages but also more 
private ways of communication (including newsgroups, chatrooms, mailing lists, e-
newsletters, and bulletin boards) were here considered.  
More studies need to be carried out on the issues here described, especially focussing on 
the clinical pharmacological and acute/chronic toxicity characteristics of the whole 
range of the PCP-like drugs.  
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Figures: 
 
Figure 1 Chemical structures of (a) PCP, (b) KET and (c) MXE. 
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Figure 2 -Diagram: Flow chart illustrating identification of the studies included over the time frame 
January 2011-October 2011. 
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Table 1 - Comparison between KET and MXE chemistry and effects 
 
Criteria KET MXE 
Chemical 
Name 
2-(2-chlorophenyl)-2-
(methylamino)cyclohexanone 
2-(3-methoxyphenyl)-2-
amino)cyclohexanone 
Chemical class PCP derivative PCP derivative 
Molecular 
weight 
237.73 g/ mol 283.79 g/ mol 
Pharmacologic
al class 
dissociative anaesthetic dissociative anaesthetic 
Receptors NMDA, σ and μ NMDA, σ and μ 
Routes of 
administration 
IV, IM, intranasal and oral intranasal, oral, sublingual, rectal, 
IM and very rarely IV 
Dosage 10 - 250 mg 10 - 100 mg 
Onset of action 30 seconds - 30 minutes 30 - 90 minutes 
Duration of 
action 
3h 0m 0s 5 - 7 h 
Desired effects depersonalization and out-of-
the-body-, including near-
death, experiences; 
stimulation. 
euphoria, empathy, cosiness, 
pleasant sensory experience, 
dissociation, derealization, vivid 
hallucinations, introspection, 
antidepressant, dissociation from 
body (‘M-hole’). 
Risk of re-dose No Yes 
Tolerance Yes Yes 
Dependance Yes Yes 
Known 
adverse effects 
confusion, vivid dreams, 
hallucination, flashbacks, 
referential thinking, panic 
attack, agitation,  
cardiovascular issues, 
depression, dissociation, 
apnoea 
confusion, dizziness, time distortion, 
aphasia, synaesthesia,  
cardiovascular issues, acute 
cerebellar toxicity and psychomotor 
agitation. 
Bladder 
toxicity 
Yes Not confirmed 
Cerebellar 
toxicity 
Not reported Anecdotally reported  
 
